Epimedokoreanin B

Epimedokoreanin B is a natural flavonoid with anticancer, anti-inflammatory and antibacterial effects. Epimedokoreanin B inhibits the growth of lung cancer cells through endoplasmic reticulum stress-mediated apoptosis accompanied by autophagosome accumulation. Epimedokoreanin B is an anti-periodontitis agent that inhibits gingipains and Porphyromonas gingivalis growth and biofilm formation . In Vitro Epimedokoreanin B (compound6; 3.13-25 μM; 48 hours) shows significate inhibitory effect on proliferation against lung cancer cell A549, Calu1 and H1299. Epimedokoreanin B displays no toxic on human bronchial epithelial cells BEAS-2B. Epimedokoreanin B treatment inhibits cell proliferation and migration accompanied by cytoplasmic vacuolation in A549 and NCI-H292 cells. Atophagosome accumulation accompanied with autophagy flux blocking is observed in Epimedokoreanin B treated cells, this was consistent with the occurrence of ER stress. Epimedokoreanin B (5 μM; 24 hours) inhibits CD163 expression and IL-10 production, which are known M2 markers, suggesting that Epimedokoreanin B inhibits M2 polarization in human monocyte-derived macrophages (HMDMs). Epimedokoreanin B suppresses STAT3 activation in HMDMs . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity AssayCell Line: A549, Calu1 and H1299 cells Concentration: 3.13 μM, 6.25 μM, 12.5 μM and 25.0 μM Incubation Time: 48 hours Result: Showed significate inhibitory effect on proliferation against lung cancer cell A549, Calu1 and H1299. Western Blot Analysis Cell Line: Human monocyte-derived macrophages (HMDMs) Concentration: 5 μM Incubation Time: 24 hours Result: Significantly suppressed IL-10-induced JAK1/STAT3 activation.and H1299. In Vivo Epimedokoreanin B (20 mg/kg; p.o; thrice a week; for 17 days) inhibits tumor growth in an LM8 tumor-bearing murine model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female C3H mice (8-10 weeks old) injected with LM8 cellsDosage: 20 mg/kg Administration: Oral administration; thrice a week; for 17 days Result: Inhibited tumor growth. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet